Watson Pharmaceuticals announced that it recently received the “Drug Supplement Application Approval Notice” for clopidogrel bisulfate tablets approved and issued by the State Drug Administration, which approved the change of marketing license holder for the drug from Zhejiang Zhongyan Pharmaceutical Technology to a company, and the drug approval number remained unchanged.

Watson Pharmaceuticals announced that it recently received the “Drug Supplement Application Approval Notice” for clopidogrel bisulfate tablets approved and issued by the State Drug Administration, which approved the change of marketing license holder for the drug from Zhejiang Zhongyan Pharmaceutical Technology to a company, and the drug approval number remained unchanged.